Applied Behavior Analysis therapy for autistic children has become one of the fastest-growing line items in state Medicaid budgets, and the money is attracting the wrong kind of attention.
The treatment—repetitive drills meant to shape behavior in young children on the autism spectrum—was once a niche service delivered by specialized nonprofits. Now it is a private-equity darling. Clinics have proliferated in strip malls from Texas to Florida, promising desperate parents evidence-based intervention while billing Medicaid for dozens of hours per child per week at rates that can exceed $100 per hour. The math is seductive: a single preschooler can generate six figures in annual revenue.
The billing bonanza
Medicaid is legally obligated to cover medically necessary treatments for children, a provision known as Early and Periodic Screening, Diagnostic, and Treatment. Once a child receives an autism diagnosis and a physician signs off on ABA therapy, the state must pay. That guarantee has turned pediatric autism care into a quasi-annuity for investors. Consolidators have rolled up dozens of small clinics, installed standardized billing software, and pushed therapists to maximize "billable hours." Former employees at several chains describe pressure to keep children in therapy longer than clinically indicated and to document sessions in ways that justify higher reimbursement codes.
State auditors are overwhelmed. Autism-related Medicaid spending has roughly tripled in many states over the past decade, yet fraud-detection units remain staffed for a pre-boom era. Texas, one of the largest Medicaid markets, has opened investigations into multiple ABA providers but secured few recoveries. The incentive structure is stacked: clinics hire lawyers who specialize in Medicaid appeals, while underfunded state agencies face backlogs measured in years.
The clinical debate
ABA itself is contested terrain. Proponents cite decades of research showing gains in communication and daily-living skills for some children. Critics—including a growing number of autistic adults—argue that the therapy's focus on compliance can be coercive and that its benefits are overstated. The controversy matters for policy: if the therapy's value is uncertain, the case for unlimited Medicaid funding weakens. Yet cutting coverage risks denying help to children who genuinely benefit. States are caught between fiscal reality and political blowback from parent-advocacy groups that treat any restriction as an attack on disabled children.
Our take
The autism-therapy boom is a case study in what happens when a well-intentioned mandate meets a fragmented, under-policed payment system. Medicaid's promise to cover necessary care for children is worth defending, but "necessary" has become whatever a for-profit clinic can get a doctor to sign. The losers are taxpayers, children subjected to excessive or ineffective treatment, and families who cannot distinguish a quality provider from a billing mill. States need real-time claims analytics, stricter credentialing, and the political will to say no to investors masquerading as healers. The alternative is a Medicaid program bled dry by the very programs meant to help its most vulnerable beneficiaries.
